Oncotarget 2018 Feb 22
Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status.
ABSTRACT
Introduction
Large cell neuroendocrine carcinomas (LCNEC) are a group of rare high grade neuroendocrine tumors that often behave clinically like small cell carcinoma (SCLC) and are treated as such. No major advancement in the management of these tumors has occurred in the last 30 years.
Methods
We present a case series of three cases from Markey Cancer center along with a review of 13 published cases in the literature wherein immune-checkpoint inhibitors were utilized in the management of LCNEC.
Results
Immune-checkpoint inhibitors might have clinical activity in LCNEC.
Conclusion
Role of immune-checkpoint inhibitors should be explored in prospective LCNEC clinical trials. We summarize current evidence regarding use of immune checkpoint inhibitors in the treatment of LCNEC.
Related Questions
Is your decision swayed by RB1 status or by duration since platinum therapy?
New answer by Medical Oncologist at St Louis Cancer Care LLP (June 13, 2021)
Let's start by backtracking to the original treatment recommendation. Since large cell neuroendocrine carcinomas (LCNEC) of the lung can harbor mutations in EGFR or BRAF or ev...